The Fibrodysplasia Ossificans Progressiva Market is undergoing a profound transformation, moving from a focus on palliative symptom management to targeted therapies that address the underlying pathology of heterotopic ossification. According to the MRFR report, the treatment landscape is segmented into corticosteroids, NSAIDs, bisphosphonates, and emerging targeted therapies. For decades, management of FOP focused on preventive care, avoiding injury, and using off-label medications such as glucocorticoids and NSAIDs to control inflammation during flare-ups. However, the approval of palovarotene and the promising clinical data for garetosmab and other pipeline drugs have ushered in a new era of disease-modifying therapies.

Palovarotene, developed by Ipsen (formerly Clementia Pharmaceuticals), was the first drug approved for FOP. It is a retinoic acid receptor gamma (RAR-γ) agonist that inhibits heterotopic ossification by modulating the BMP signaling pathway. Palovarotene is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged ≥8 years for females and ≥10 years for males with FOP. While its approval was a major breakthrough, the drug is associated with safety concerns, including premature growth plate closure (PPC) in skeletally immature patients, leading to strict dosing restrictions and risk management strategies. A narrative review published in 2025 highlighted that while palovarotene shows promise in managing FOP, safety concerns and the complexities of clinical trial implementation highlight the need for innovative approaches to ensure effective and equitable treatments.

Garetosmab, developed by Regeneron Pharmaceuticals, represents a potentially significant advance in FOP treatment. Garetosmab is a fully human monoclonal antibody designed to target and neutralize Activin A, a potent driver of heterotopic ossification. In February 2026, the FDA accepted Regeneron's biologics license application for garetosmab under Priority Review, setting a target decision date of August 2026. If approved, garetosmab would become the first and only therapy shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP. The positive Phase 3 OPTIMA trial enrolled 63 participants and demonstrated remarkable efficacy: the 3 mg/kg dose achieved a 94% reduction in new HO lesions, while the 10 mg/kg dose achieved a 90% reduction, compared to placebo. A post-hoc analysis revealed even more striking results, with both doses demonstrating a greater than 99% reduction in mean total volume of new HO lesions. A second Phase III study (OPTIMA 2) is planned to begin later in 2026 to evaluate garetosmab in pediatric and adolescent patients.

Other pipeline therapies include fidrisertib (IPN60130) , an oral small molecule being developed by Ipsen (formerly Clementia Pharmaceuticals). A Phase 2 study is currently evaluating the efficacy of two dosing regimens of IPN60130 in inhibiting new HO volume in adult and pediatric participants with FOP. The study uses low-dose whole-body CT to assess changes in heterotopic ossification. Gene therapy approaches, which offer the possibility of correcting the faulty ACVR1 gene, are also in early stages of development. As more targeted therapies enter the market and gain regulatory approval, the treatment landscape for FOP will continue to evolve, offering patients a range of options to manage their disease and improve their quality of life.